Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions

Jennifer Moritz,Antonia Schwab,Andreas Reinisch,Armin Zebisch,Heinz Sill,Albert Wölfler

DOI: https://doi.org/10.3390/biomedicines12030599

IF: 4.757

2024-03-08

Biomedicines

Abstract:Acute myeloid leukemia (AML) is an aggressive malignant disease with a high relapse rate due to the persistence of chemoresistant cells. To some extent, these residual cells can be traced by sensitive flow cytometry and molecular methods resulting in the establishment of measurable residual disease (MRD). The detection of MRD after therapy represents a significant prognostic factor for predicting patients' individual risk of relapse. However, due to the heterogeneity of the disease, a single sensitive method for MRD detection applicable to all AML patients is lacking. This review will highlight the advantages and limitations of the currently available detection methods—PCR, multiparameter flow cytometry, and next generation sequencing—and will discuss emerging clinical implications of MRD test results in tailoring treatment of AML patients.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

What problem does this paper attempt to address?

This paper aims to address the challenges faced by Measurable Residual Disease (MRD) detection in Acute Myeloid Leukemia (AML) and explore future development directions. Specifically, the paper focuses on the following aspects:

1. **Importance of MRD Detection**: MRD detection is of great significance in assessing the recurrence risk of patients after AML treatment. Through sensitive flow cytometry and molecular methods, chemoresistant cells remaining after chemotherapy can be tracked, and these cells may be potential precursors leading to recurrence. Therefore, MRD detection has become a key concept in AML treatment.

2. **Limitations of Current Detection Methods**:
- **Polymerase Chain Reaction (PCR)**: Although the PCR method has high sensitivity (10\(^{-4}\) to 10\(^{-6}\)), it is only applicable to about 40 - 50% of AML patients because not all patients have specific mutations or translocations.
- **Multiparameter Flow Cytometry (MFC)**: The MFC method is applicable to almost all patients, but its sensitivity is relatively low (10\(^{-3}\) to 10\(^{-4}\)), and the degree of standardization is not high, and the results are greatly affected by the operator's experience.
- **Next - Generation Sequencing (NGS)**: The NGS method can analyze multiple genes simultaneously and is applicable to a wider patient population, but it has difficulty in distinguishing true AML - specific mutations from clonal hematopoiesis mutations.

3. **Future Improvement Directions**:
- **Standardized PCR Detection**: Improve the reliability and comparability of PCR detection through standardization and quality control.
- **Optimized Flow Cytometry**: Develop and validate antibody panels to achieve standardized MFC - MRD assessment, and may further improve the accuracy through automated methods.
- **Combination Method**: Combine the methods of MFC and targeted NGS to improve the sensitivity and specificity of MRD detection, especially in distinguishing clonal hematopoiesis and truly residual leukemia cells.

In conclusion, by reviewing the current MRD detection methods and their advantages and disadvantages, this paper proposes future improvement directions, aiming to improve the accuracy and clinical application value of MRD detection in AML patients.